These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
105 related articles for article (PubMed ID: 2852947)
41. Etoposide dosage and pharmacodynamics. Joel SP; Shah R; Slevin ML Cancer Chemother Pharmacol; 1994; 34 Suppl():S69-75. PubMed ID: 8070031 [TBL] [Abstract][Full Text] [Related]
42. Phase I and pharmacokinetic study of etoposide phosphate by protracted venous infusion in patients with advanced cancer. Soni N; Meropol NJ; Pendyala L; Noel D; Schacter LP; Gunton KE; Creaven PJ J Clin Oncol; 1997 Feb; 15(2):766-72. PubMed ID: 9053503 [TBL] [Abstract][Full Text] [Related]
43. A phase I trial of carboplatin and etoposide for elderly (>or=75 year-old) patients with small-cell lung cancer. Fukuda M; Soda H; Soejima Y; Fukuda M; Kinoshita A; Takatani H; Kasai T; Nagashima S; Kawabata S; Doi S; Kohno S; Oka M Cancer Chemother Pharmacol; 2006 Nov; 58(5):601-6. PubMed ID: 16463061 [TBL] [Abstract][Full Text] [Related]
44. Paclitaxel, carboplatin, and extended-schedule oral etoposide for small-cell lung cancer. Hainsworth JD; Hopkins LG; Thomas M; Greco FA Oncology (Williston Park); 1998 Jan; 12(1 Suppl 2):31-5. PubMed ID: 9516609 [TBL] [Abstract][Full Text] [Related]
45. [Phase II study of a continuous five-day intravenous infusion of cisplatin and etoposide with concurrent chest radiation therapy in limited stage small cell lung cancer]. Sugita T; Matsunaga K; Kobayashi H; Horikawa S; Suzuki Y; Nishiyama H; Maekawa N; Matsumoto H; Okazaki M; Katagami N Gan To Kagaku Ryoho; 1994 Oct; 21(14):2479-83. PubMed ID: 7944494 [TBL] [Abstract][Full Text] [Related]
47. A phase II study of ifosfamide in combination with etoposide and cisplatin in the treatment of extensive small cell lung cancer. Evans WK; Stewart D; Logan D; Maroun J; Goss G; Shepherd FA; Latreille J; Warner E; Dahrouge S Semin Oncol; 1992 Dec; 19(6 Suppl 12):51-6. PubMed ID: 1336622 [TBL] [Abstract][Full Text] [Related]
48. A phase I study of ifosfamide/carboplatin/etoposide/paclitaxel in advanced lung cancer. Strauss GM; Lynch TJ; Elias AD; Jacobs C; Kwiatkowski DJ; Shulman LN; Carey RW; Grossbard ML; Jauss S; Sugarbaker DJ Semin Oncol; 1995 Aug; 22(4 Suppl 9):70-4. PubMed ID: 7544029 [TBL] [Abstract][Full Text] [Related]
49. Phase II study of area under the plasma-concentration-versus-time curve-based carboplatin plus standard-dose intravenous etoposide in elderly patients with small-cell lung cancer. Okamoto H; Watanabe K; Nishiwaki Y; Mori K; Kurita Y; Hayashi I; Masutani M; Nakata K; Tsuchiya S; Isobe H; Saijo N J Clin Oncol; 1999 Nov; 17(11):3540-5. PubMed ID: 10550152 [TBL] [Abstract][Full Text] [Related]
50. Pharmacokinetic comparison of oral and intravenous etoposide in patients treated with the CHOEP-regimen for malignant lymphomas. Kroschinsky FP; Friedrichsen K; Mueller J; Pursche S; Haenel M; Prondzinsky R; Ehninger G; Schleyer E Cancer Chemother Pharmacol; 2008 Apr; 61(5):785-90. PubMed ID: 17579865 [TBL] [Abstract][Full Text] [Related]
51. Phase I study of high-dose continuous intravenous infusion of VP-16 in combination with high-dose melphalan followed by autologous bone marrow transplantation in children with stage IV neuroblastoma. Valteau-Couanet D; Vassal G; Pondarré C; Bonnay M; Benhamou E; Couanet D; Plantaz D; Hartmann O Bone Marrow Transplant; 1996 Apr; 17(4):485-9. PubMed ID: 8722343 [TBL] [Abstract][Full Text] [Related]
52. Phase II and pharmacokinetic/pharmacodynamic trial of sequential topoisomerase I and II inhibition with topotecan and etoposide in advanced non-small-cell lung cancer. Dowlati A; Levitan N; Gordon NH; Hoppel CL; Gosky DM; Remick SC; Ingalls ST; Berger SJ; Berger NA Cancer Chemother Pharmacol; 2001; 47(2):141-8. PubMed ID: 11269740 [TBL] [Abstract][Full Text] [Related]
53. Effect of grapefruit juice intake on etoposide bioavailability. Reif S; Nicolson MC; Bisset D; Reid M; Kloft C; Jaehde U; McLeod HL Eur J Clin Pharmacol; 2002 Oct; 58(7):491-4. PubMed ID: 12389073 [TBL] [Abstract][Full Text] [Related]
54. A phase I study of etoposide phosphate administered as a daily 30-minute infusion for 5 days. Thompson DS; Greco A; Miller AA; Srinivas NR; Igwenezue KB; Hainsworth JD; Schacter LP; Kaul S; Barbhaiya RH; Garrow C Clin Pharmacol Ther; 1995 May; 57(5):499-507. PubMed ID: 7768072 [TBL] [Abstract][Full Text] [Related]
55. Phase II study of 21 day schedule oral etoposide in children. New Agents Group of the United Kingdom Children's Cancer Study Group (UKCCSG). Davidson A; Gowing R; Lowis S; Newell D; Lewis I; Dicks-Mireaux C; Pinkerton CR Eur J Cancer; 1997 Oct; 33(11):1816-22. PubMed ID: 9470839 [TBL] [Abstract][Full Text] [Related]
56. Dose intensity phase I/II trial with carboplatin, ifosfamide, etoposide and vincristine combined with filgrastim in patients with small-cell lung cancer. Hanauske AR; Korfel A; Perker M; Heinrich B; Schwab G; Graf M; Depenbrock H; Höffken G; Kreuser ED; Thiel E; Zwingers T; Berdel WE Oncology; 1997; 54(5):363-70. PubMed ID: 9260596 [TBL] [Abstract][Full Text] [Related]
57. A Phase I-II study of sequential administration of topotecan and oral etoposide (toposiomerase I and II inhibitors) in the treatment of patients with small cell lung carcinoma. Mok TS; Wong H; Zee B; Yu KH; Leung TW; Lee TW; Yim A; Chan AT; Yeo W; Chak K; Johnson P Cancer; 2002 Oct; 95(7):1511-9. PubMed ID: 12237920 [TBL] [Abstract][Full Text] [Related]
58. Schedule-dependent topoisomerase II-inhibiting drugs. Joel SP; Slevin ML Cancer Chemother Pharmacol; 1994; 34 Suppl():S84-8. PubMed ID: 8070033 [TBL] [Abstract][Full Text] [Related]
60. High-dose etoposide therapy for extensive small cell lung cancer: a Cancer and Leukemia Group B Study. Luikart SD; Propert KJ; Modeas CR; Green MR; Perry MC Cancer Treat Rep; 1987 May; 71(5):533-4. PubMed ID: 3032434 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]